Sinopharm Refutes Claim Of Increasing Stake In Sinopharm Medicine Holding
This article was originally published in PharmAsia News
Executive Summary
In response to a China Times article that said Sinopharm plans to increase its stake in Sinopharm Medicine Holding by 30 percent, which would delay the latter's listing in Hong Kong, Sinopharm has issued a statement refuting the claim. It denied seeking approval from relevant authorities for the move. Fosun Pharma, the second largest shareholder of Sinopharm Medicine Holding, also released an announcement rejecting the report published on March 18. (Click here for more - Chinese Language)